Clinical trial NCT04881110
Conditions: Type 2 Diabetes Peripheral Arterial Disease
Keywords: Type 2 diabetes Liraglutide Transcutaneous Oxygen Tension Peripheral arterial disease Inflammation Angiogenesis Endothelial Dysfunction Diabetic microvascular complications
Sponsor: University of Campania Luigi Vanvitelli
Start date: 2021-02-01; Completion date: 2022-12-31
Enrollment: 60 participants; Allocation: RANDOMIZED; Intervention model: PARALLEL

Brief summary:
STARDUST is an open-label, two-arm randomized controlled trial, aimed at evaluating the effects of liraglutide on peripheral perfusion, as compared with the aggressive treatment of cardio-metabolic risk factors, in people with type 2 diabetes and peripheral artery disease. The potential benefits for participants in the study include the possibility of improving peripheral perfusion with drugs that have been evaluated as effective in controlling diabetes and safe and protective for cardiovascular health.

The primary outcome of the study is the change of peripheral transcutaneous oxygen tension between groups at three and six months. Participants in the study will be followed for 6 months in order to evaluate the effects of liraglutide and the change of other secondary outcomes.

Detailed description:
An 18-month extension of the follow-up will be performed for all the study population, according to guidelines and good clinical practice. The follow-up will include the glyco-metabolic parameters and the main cardiovascular risk factors, including TcPO2 assessment.

Data from this extended observation will be collected for additional analyses (mostly regarding the durability of the effects). Individuals who will be lost during follow-up and/or discontinue or modify the glucose-lowering treatment will be excluded from the analyses.

Arms: arm 1: Patients in this arm will receive liraglutide, according to the current clinical practice. arm 2: Patients in this arm will be strictly monitored with optimization of the therapy for atherosclerosis major risk factors.
Interventions: intervention 1: Liraglutide intervention 2: Control
Intervention descriptions: intervention 1: Patients in this arm will receive one daily subcutaneous injection of liraglutide. The starting dose is 0.6 mg/dl per day. The dose has to be increased to 1.2 mg/dl per day after the first week of treatment and to 1.8 mg/dl after the second one. intervention 2: Patients in this arm will be strictly monitored for atherosclerosis major risk factors, such as hypertension and dyslipidemia, and treated according to current clinical practice.

Protocol documents:
Prot_000.pdf: 
1 
 
EFFECTS OF THE GLP-1 RECEPTOR AGONIST LIRAGLUTIDE ON LOWER LIMB 
PERFUSION IN PEOPLE WITH TYPE 2 DIABETES AND PERIPHERAL ARTERY 
DISEASE: A RANDOMIZED CONTROLLED TRIAL (STARDUST) 
 
ClinicalTrials.gov identification number: NCT04881110 
Study Protocol (version 2_0401_2021) 
 
Principal investigator: Prof. Katherine Esposito 
Full professor of Endocrinology and Metabolic Diseases, University of Campania Luigi Vanvitelli 
Chief of the Division of Endocrinology and Metabolic Diseases, University Hospital of Campania 
Luigi Vanvitelli 
 
 
Introduction 
Diabetes represents a severe social and health burden. Among chronic complications of diabetes, 
peripheral artery disease (PAD) is involved in diabetic foot ulcer onset and prognosis. PAD 
diagnosis is based on several assessments: ankle-brachial index (ABI) is a common and simple 
evaluation. However, it can often be unreliable because of arterial calcification, which is frequent in 
people with diabetes. Transcutaneous oxygen tension (TcPO2) evaluation is a non-invasive 
approach to measure tissue’s perfusion and oxygenation. Moreover, it is currently recommended to 
detect the grade of peripheral ischemia in individuals with diabetic foot ulcers. Furthermore, low 
values of TcPO2 have been associated with the high risk of lower limb amputation, reduction of the 
healing rate and major cardiovascular events. 
Optimal glycemic control has been related to the reduction of the incidence of chronic 
complications of diabetes. Moreover, among novel glucose-lowering therapies, GLP-1 receptor 
agonists (GLP-1RAs) have proven over time cardiovascular benefits in cardiovascular outcome 
trials. Indeed, GLP-1 receptors are widely expressed in endothelial and cardiovascular cells; this 
may contribute to improve endothelial function and angiogenesis, prevent endothelial cells 
apoptosis and reduce oxidative stress and inflammation. 
GLP-1RAs have determined a significant reduction of major cardiovascular events in 
cardiovascular outcome trials in people with type 2 diabetes. Moreover, a post-hoc analysis of 
LEADER trial has described the safety of liraglutide (vs. placebo) in terms of risk of diabetic foot 
ulcers and/or infection and peripheral revascularization. Of interest, a significant reduction of the 
incidence of lower extremities amputation occurred in participants of the study with diabetic foot 
syndrome who were treated with liraglutide. 
 


2 
 
Aims 
“Effects of the GLP-1 receptor agonist liraglutide on lower limb perfusion in people with type 2 
diabetes and peripheral artery disease: a randomized controlled trial (STARDUST)” is designed to 
determine the effect of injectable liraglutide on peripheral perfusion in individuals with type 2 
diabetes and PAD. Peripheral perfusion will be assessed through the TcPO2 measurement on the 
foot. Moreover, we will evaluate the effect of GLP-1RAs on parameters of glyco-metabolic control, 
inflammation, angiogenesis and cardiovascular risk markers. Particularly, we will analyze: 
- 
glyco-metabolic parameters [fasting glucose, glycated hemoglobin (HbA1c), weight, body 
mass index (BMI), waist circumference, systolic and diastolic blood pressure]; 
- 
lipid profile (total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides); 
- 
inflammation markers [C-reactive protein (CRP), fibrinogen, tumor necrosis factor alpha, 
interleukin-6]; 
- 
renal function parameters [creatinine, azotemia, urine albumin to creatinine ratio (UACR), 
glomerular filtration rate (eGFR)]; 
- 
angiogenesis markers [endothelial progenitor cells (EPCs) and vascular endothelial growth 
factor (VEGF)]; 
- 
PAD clinical assessment (ABI, 6-minutes walking test); 
- 
sexual hormones levels and sexual function. 
Study design 
STARDUST is a single-center, randomized clinical trial lasting 24 weeks. The study will include a 
screening visit, a randomization visit and 2 follow-up visits (3 month and 6 month). 
 
 
 
 
 


3 
 
Study population 
Eligibility will be considered for individuals with type 2 diabetes aged > 35 years, PAD diagnosed 
through doppler ultrasound, angio-CT, angiography in the past 12 months, TcPO2 value of the foot 
ranged between 49 and 30 mmHg. 
Inclusion criteria 
- 
diagnosis of type 2 diabetes 
- 
HbA1c ranged between 6.5% and 8% 
- 
Glucose-lowering therapy with metformin and/or insulin on stable doses for at least 3 
months 
Exclusion criteria 
- 
diagnosis of type 1 diabetes 
- 
current or recent treatment with GLP-1RAs and/or DDP-4 inhibitors 
- 
participation to other clinical research, including drug administration 
- 
contraindications to the treatment with GLP-1RAs 
- 
plans for pregnancy or current pregnancy or breast feeding 
- 
history of thyroid disease 
- 
inflammatory bowel disease 
- 
acute coronary and/or cerebravascular disease within the previous 14 days 
- 
plans and/or indications to peripheral revascularization procedure 
- 
estimated glomerular filtration rate (eGFR) below 15 ml/min per 1.73m2 
- 
previous history or current diagnosis of neoplasms and/or anti-neoplastic therapies within 5 
years from randomization 
- 
history of diabetic chetoacidosis 
- 
current therapies with steroids and/or anti-psychotic medications 
- 
any concomitant conditions which can preclude participation in the study 
Female participants in fertile age have to use contraceptives during the study. Moreover, women 
who meet inclusion criteria will be screened for pregnancy before the completion of the enrollment. 
Randomization 
Randomization using a computer generated random-number sequence. 
Allocation 
Concealed in sealed study folders that will be held in a central, secured location until after informed 
consent will be obtained. 
Interventions 
LIRA GROUP: participants assigned to LIRA group will start on 0.6 mg once daily liraglutide 
subcutaneous injection at approximately the same time of the day. The dose will be titrated up on a 
weekly schedule by 0.6 mg increase to a target dose of 1.8 mg or the maximum tolerated. In 
accordance with standards of medical care, cardiovascular risk factors will be managed as follows: 


4 
 
systolic blood pressure below 130 mmHg and diastolic blood pressure below 80 mmHg obtained, if 
needed, with ACE inhibitors or angiotensin receptor blockers, LDL-cholesterol below 70 mg/dL, 
aspirin therapy at the dosage of 100 mg daily or alternatively clopidogrel 75 mg daily in case of 
documented aspirin allergy. 
CONTROL GROUP: individuals assigned to control group will be given, if needed, tailored 
therapeutic prescriptions to manage blood glucose levels and cardiovascular risk factors, according 
to the standards of medical care. The established treatment goals for cardiovascular risk factors 
control will be: systolic blood pressure below 130 mmHg and diastolic blood pressure below 80 
mmHg obtained, if needed, with ACE inhibitors or angiotensin receptor blockers, LDL-cholesterol 
below 70 mg/dL, aspirin therapy at the dosage of 100 mg daily or alternatively clopidogrel 75 mg 
daily in case of documented aspirin allergy. 
Recruitment and time schedule 
Recruitment will last 18 months. Participants will be followed up for 24 weeks (6 months). 
 
 
Time schedule 
Visit 1 
(Screening) 
 
 
Week -1 
Visit 2 
(Randomization) 
 
 
Week 0 
Visit 3 
(3 months 
follow-
up) 
 
Week 12 
Visit 4 
(End of 
the 
study) 
 
Week 24 
Informed consent 
x 
 
 
 
Eligibility evaluation 
x 
 
 
 
Pregnancy screening test† 
x 
 
 
 
Start of the intervention 
 
x 
 
 
Anamnesis and clinical assessment 
x 
 
 
 
Physical examination: weight, BMI, 
WC 
 
x 
x 
x 
Blood pressure evaluation 
 
x 
x 
x 
Glycemic profile evaluation: fasting 
glucose, HbA1c 
x 
x 
x 
x 
Lipid 
profile 
evaluation: 
total 
cholesterol, LDL-chol, HDL-chol and 
triglycerides 
 
x 
x 
x 
Renal fuction evaluation: creatinine, 
azotemia, eGFR 
x 
x 
x 
x 
Inflammation 
markers: 
CRP, 
fibrinogen, TNF-α and IL-6 
 
x 
 
x 
Angiogenesis markers: EPCs and 
VEGF 
 
x 
 
x 
Sexual 
hormones 
evaluation: 
testosterone or estradiol, LH, FSH, 
SHBG* 
 
x 
 
x 
Albuminuria 
 
x 
 
x 


5 
 
ABI and 6-minute walking test 
 
x 
 
x 
TcPO2 
x 
x 
x 
x 
IIEF-5 questionnaire* 
 
x 
 
x 
FSFI questionnaire † 
 
 
 
 
Adverse events evaluation 
 
x 
x 
x 
*In males; †In females. 
ABI, Ankle Brachial Index; BMI, Body Mass Index; CRP, C-reactive protein; EPC, Endothelial Progenitor Cell; eGFR, 
estimated Glomerular Filtration Rate; FSFI, Female Sexual Function Index; FSH, Follicle-stimulating hormone; IL-6, 
Interleukin 6; IIEF-5, International Index of Erectile Function 5; LH, Luteinizing hormone; SHBG, Sex hormone-
binding globulin; TcPO2, Transcutaneous Oxygen Pressure; TNF-α, Tumor Necrosis Factor α; VEGF, Vascular 
Endothelial Growth Factor; WC, Waist circumference. 
Study withdrawal 
Subjects may withdraw from the research at any time for: 
- 
voluntary retirement; 
- 
occurrence of adverse event which requires the end of the study; 
- 
poor adherence to trial intervention and/or follow-up; 
- 
modification of inclusion/exclusion criteria from baseline; 
- 
novel treatment with medications interfering with the endpoints evaluation; 
- 
pregnancy. 
Investigators may interrupt the research in case of: 
- 
occurrence of adverse events (nausea, vomit, abdominal pain, fever, rush and/or 
eosinophilia); 
- 
renal function worsening (eGFR <15 mL/min/1.73m2); 
- 
dialysis or renal transplantation; 
- 
chetoacidosis (confirmed by laboratory tests); 
- 
occurrence of acute or chronic pancreatitis; 
- 
medullary carcinoma diagnosis after randomization; 
- 
any adverse event or relevant clinical event, considered as an interference for the research; 
- 
any allergic reactions; 
- 
recruitment of the individual in other study interfering with the research. 
Primary outcomes 
The co-primary outcomes of the study are the peripheral perfusion assessed at baseline and at the 
end of the study and the proportion of individuals who reaches a 10% increase of the TcPO2 value 
from the baseline in each group. The change of TcPO2 of the foot in people treated with liraglutide 
compared with individuals of the Control group will be calculated after 6 months. The TcPO2 
change will be evaluated as the difference between TcPO2 values measured at the end of the trial 
and baseline. 
Secondary outcomes 
The secondary outcomes of the study are the change (measured as the difference of variables at the 
end of the trial vs. baseline) in glyco-metabolic, inflammation and angiogenesis, atherosclerosis 


6 
 
parameters in people treated with liraglutide compared with individuals of the Control group. 
Moreover, we will evaluate the changes in renal function, sexual hormones levels and sexual 
function. 
18-month extension of the follow-up 
An 18-month extension of the follow-up will be performed for all the study population, according to 
guidelines and good clinical practice. The follow-up will include the glyco-metabolic parameters 
and the main cardiovascular risk factors, including TcPO2 assessment. 
Data from this extended observation will be collected for additional analyses (mostly regarding the 
durability of the effects). Individuals who will be lost during follow-up and/or discontinue or 
modify the glucose-lowering treatment will be excluded from the analyses. 
Methods 
All individuals will be informed about the aims of the study through a specific information letter. 
Moreover, during the screening visit, we will collect written informed consent and deliver an 
information letter for the general practitioner of each participant. 
Physical examination - Height and weight will be recorded using the Seca 200 scale, with attached 
altimeter (Seca, Hamburg, Germany). The WC will be measured in orthostatic position, at anterior-
superior iliac spine, using a graduated instrument. BMI will be calculated as weight in kg divided 
by the height in squared meters (kg/m2). Blood pressure will be measured three times, with patients 
in sitting position, after at least 15 minutes of rest. 
Laboratory assessments – Blood samples will be collected for the evaluation of glycemia, HbA1c, 
creatinine, serum lipids, according to the attached time-schedule. Calculation of the glomerular 
filtration rate will be performed using the MDRD formula. Participants will be tested for levels of 
testosterone, estradiol, LH, FSH and SHBG according to sex.  Serum lipids will be determined by 
enzyme immunoassay. Albuminuria will be measured on 24-hour urine sample and defined as 
microalbuminuria for urinary albumin excretion values between 30 and 299 mg/24h and 
macroalbuminuria for values greater than 300 mg/24h. 
Inflammation - Serum samples for cytokines, CRP and VEGF will be stored at -80°C until 
measurements will be performed. Serum concentrations of IL-6, TNF-α and VEGF will be 
determined in duplicate using highly sensitive immunoenzymatic kits (Quantikine HS, R&D 
System, Minneapolis, Minn). High sensitivity CRP will be measured by immunonephelometric 
method. 
Determination of circulating levels of EPCs - Each patient will provide a blood sample to determine 
EPCs count. Cells derived from peripheral blood will be studied for the evaluation of surface 
antigen expression by flow cytometry. Mononuclear cells will be isolated from peripheral venous 
blood by density gradient centrifugation and subsequently incubated for 30 min at 4°C in dark field 
with monoclonal antibodies conjugated to fluorescein isothiocyanate (FITC) for human CD34+ 
cells (MAb) (Becton Dickinson, Buccinasco, Bologna, Italy), phycoerythrin (PE) conjugated 
antibodies for human KDR+ cells (MAB) (R&D Systems, Minneapolis, MN, USA), and 
allophycocyanin (APC) conjugated antibodies for human CD133+ cells (Miltenyi Biotec, Calderara 


7 
 
di Reno, Bologna, Italy). After incubation, a quantitative analysis will be performed using BD 
FACSCalibur and 1,000,000 events will be acquired from each sample. The use of a morphological 
gate will be employed for the exclusion of granulocytes. Subsequently, CD34+ or CD133+ cells 
will be identified in the mononuclear cell fraction and these populations will be examined for 
simultaneous expression of KDR. CD34+CD133+ cells will be identified in the two-dimensional 
analysis of the dot-plots. The KDR+ mononuclear cell pool will be identified separately. Cells with 
triple positivity for the considered markers will be searched within the group of CD34+ cells, due to 
the double expression of KDR and CD133. Data will be processed using the Macintosh CELLquest 
software (Becton Dickinson). The set-up of the instrument will be optimized daily by analyzing the 
expression of lymphocytes derived from peripheral blood labeled with antiCD4Fitc/CD8, Pe/CD3, 
Pecy5/CD45 Apc 4-, in combination of 4 colors. 
Clinical assessment of atherosclerosis – The ABI of both limbs will be calculated through the ratio 
between the systolic pressure registered at the posterior tibial artery and the systolic pressure 
recorded at the brachial artery, after at least 15 minutes of rest and in the supine position. The 6-
minute walking test will be performed by each participant, walking up and down in a 100 meters 
hallway. Individuals will receive instructions to cover as much distance as possible in 6 minutes. 
Erectile Function Assessment - Male patients will perform a self-assessment test (IIEF-5) of their 
erectile function and overall satisfaction with sexual life, referring to the previous 6 months. 
Erectile dysfunction (ED) will be classified based on the total questionnaire score. Any score ≤ 21 
will indicate the presence of ED [mild (score 21-17), mild-moderate (score 16 -12), moderate (score 
11-8) and severe (score 7-1)]. The IIEF-5 questionnaire will be administered at visit 2 (week 0) and 
at the end of the study (week 24). 
Assessment of Female Sexual Function – Female sexual function will be studied through the FSFI 
questionnaire which assesses sexual activity over the past 4 weeks and includes 19 questions. The 
questionnaire will investigate six distinct domains (sexual desire, arousal, lubrication, orgasm, 
satisfaction and pain), and provide a total score indicative of global sexual function. A total FSFI 
score < 26.55 will be used to classify the presence of female sexual dysfunction. The FSFI 
questionnaire will be administered at visit 2 (week 0) and at the end of the study (week 24). 
Evaluation of TcPO2 - The measurement of transcutaneous oxygen tension will be performed on 
both limbs of each participant. Anterior tibial artery perfusion will be assessed near the base of the 
third finger, while posterior tibial artery perfusion will be evaluated near the lateral malleolus. The 
patients will be examined in supine position, after 20 minutes of rest. The application of the 
electrodes has to avoid areas with bony prominences, superficial veins or skin lesions. Measurement 
sites will be cleaned with an alcoholic solution, the electrodes will be fixed to the skin through an 
adhesive ring, after the application of a contact solution. Before each measurement, the oximeter 
will be calibrated for at least 10 minutes. The TcPO2 measurement will be recorded for 16 minutes. 
According to manufacturer sheet, TcPO2 value ≥50 mmHg is considered as indicator of a normal 
perfusion, while TcPO2 value <30 mmHg is referred to critical ischemia. The lowest value of each 
participant will be considered for the follow-up and the analysis. 
Planned statistical analysis 


8 
 
The sample size calculation was performed based on the change of the primary endpoint (change in 
TcPO2). Assuming an estimated standard deviation of 5 mmHg, a dropout rate of 10%, we expect to 
require at least 50 participants (in a 1:1 ratio LIRA:Control strategies) to achieve the 90% power to 
detect an 10% difference between group at a α-level of 0.05. 
Descriptive statistics will be used for demographic and baseline clinical characteristics of all 
participants in the study. Continuous variables will be described as either mean and standard 
deviation (SD) or medians and interquartile range (IQR) according to sample distribution, and count 
data will be reported as numbers and percentages. Comparisons of baseline data between groups 
will be performed by Student’s t test or Mann–Whitney Rank Sum test, depending on the normality 
of sample distribution. Comparison among frequencies was made with the χ2 test. 
To evaluate the change of variables over time Δ values will be calculated as value at the last 
observation minus value at the start. The paired t test and Wilcoxon signed rank test within each 
patients’ group will be used to assess changes in the studied variables from baseline to the last 
observation. Two-sample t-test will be used to compare differences between interventions. The χ2 
test will be used for comparing proportions of participants in the 2 groups who reached the primary 
endpoint after the intervention. Relative Risk (RR) and 95% confidence interval (CI) will be 
calculated to demonstrate the relationship between the intervention and the achievement of the 
primary endpoint. Data were also analyzed by analysis of variance for repeated measures with a 
post-hoc comparisons made with the Scheffé’s test. P value < 0.05 will be considered statistically 
significant. All analyses will be conducted using SPSS version 19.0 (SPSS Inc, Chicago, Ill). 
Safety and Adverse Events 
Adverse event (AEs) - Any unexpected event occurred in a patient included in a clinical trial after 
the administration of a pharmacological product. This event is not necessarily related to 
pharmacological treatment. Therefore, an AE, may be any unpleasant and unwanted clinical sign 
(for example, an abnormal laboratory finding), symptom, or disease, which is transiently associated 
with the use of a drug. According to the guidelines of the Common Terminology Criteria for 
Adverse Events (https://www.fda.gov/downloads/Guidances/ UCM174090.pdf), AEs will be 
divided in different grades. 
- Grade 1 (mild): lack of symptoms or mild symptoms, with no indication to specific intervention; 
clinical or diagnostic observation is required. 
- Grade 2 (moderate): moderate symptoms requiring local or non-invasive intervention; it may 
determine a limitation of daily activities. 
- Grade 3 (severe or clinically significant, but not immediately life-threatening): requiring 
hospitalization. It may determine disability and heavily limit daily activities. 
- Grade 4 (life-threatening event): indication to urgent intervention. 
- Grade 5: death related to AE. 
Adverse drug reaction (ADR) - An ADR is defined as a noxious and unintended response to drug 
administration. It occurs determining pathological changes with doses which are normally used in 


9 
 
humans for prophylaxis, diagnosis, or therapy of a disease. The relationship between the drug 
administration and the adverse event is reasonably possible and, in any case, cannot be excluded. 
Serious Adverse Event (SAE) – A SAE is defined as any adverse clinical event that is fatal or life-
threatening, which requires hospitalization and leads to a significant disability. It also includes 
congenital anomalies/birth defects, or any serious medical event that investigator would report. 
Hospitalization will be considered as SAE if: 
- duration of hospitalization lasts more than 12 hours; 
- hospitalization was not previously planned; 
- hospitalization is not connected to an AE. 
Disability is defined as the significant loss of any ability useful for carrying out normal vital 
functions. 
Unexpected Adverse Reaction or Suspected Unexpected Serious Adverse Reaction (SUSAR) – A 
SUSAR is a severe and unexpected reaction which is also considered unpredictable, according to 
drug information (for example, medication data sheet). 
Overview of Adverse Event Evaluation 
- 
Type, frequency, severity and severity/intensity of all AEs 
- 
Number of patients discontinuing treatment due to the occurrence of any AE 
- 
Clinically significant changes in ECG, vital signs and laboratory tests 
If any AE/SAE occurs, investigator will have the responsibility to report the suspected adverse drug 
reaction to the Service of Pharmacovigilance, in accordance with current legislation. Moreover, 
serious adverse events must be notified to pharmacovigilance manager within 24 hours of the 
awareness. Furthermore, SUSARs must be notified to the Authorities and Ethical Committee. 
Pregnancy 
Pregnancy is an exclusion criteria for the study, since GLP-1RAs have no indications in pregnancy. 
If pregnancy occurs in patients taking liraglutide: 
1) treatment with liraglutide will be immediately stopped; 
2) pharmacovigilance manager will receive notification (within 24 hours); 
3) women will be monitored until the end of the pregnancy. 
 
 
 
 


10 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
References 
1) Saeedi P, Petersohn I, Salpea P, et al. Global and regional diabetes prevalence estimates for 
2019 and projections for 2030 and 2045: Results from the International Diabetes Federation 
Diabetes Atlas, 9th edition. Diabetes Res Clin Pract. 2019;57:107843. doi: 
10.1016/j.diabres.2019.107843. 
2) Beagley J, Guariguata L, Weil C, et al. Global estimates of undiagnosed diabetes in adults. 
Diabetes Res Clin Pract. 2014;103(2):150-60. doi: 10.1016/j.diabres.2013.11.001. 
3) Gerstein HC. Diabetes: Dysglycaemia as a cause of cardiovascular outcomes. Nat Rev 
Endocrinol. 2015;11(9):508-10. doi: 10.1038/nrendo.2015.118. 
4) Potier L, Abi Khalil C, Mohammedi K, Roussel R. Use and utility of ankle brachial index in 
patients with diabetes. Eur J Vasc Endovasc Surg. 2011;41(1):110-6. doi: 
10.1016/j.ejvs.2010.09.020. 
5) Nam SC, Han SH, Lim SH, et al. Factors a ecting the validity of ankle–brachial index in the 
diagnosis of peripheral arterial obstructive disease. Angiology. 2010;61(4):392-6. doi: 
10.1177/0003319709348295. 


11 
 
6) Potier L, Halbron M, Bouilloud F, et al. Ankle-to-brachial ratio index underestimates the 
prevalence of peripheral occlusive disease in diabetic patients at high risk for arterial 
disease. Diabetes Care. 2009;32(4):e44. doi: 10.2337/dc08-2015. 
7) Rooke TW, Osmundson PJ. The influence of age, sex, smoking, and diabetes on lower limb 
transcutaneous oxygen tension in patients with arterial occlusive disease. Arch Intern Med. 
1990;150(1):129-32. 
8) Gazzaruso C, Coppola A, Falcone C, et al. Transcutaneous oxygen tension as a potential 
predictor of cardiovascular events in type 2 diabetes: comparison with ankle-brachial index. 
Diabetes Care. 2013;36(6):1720-5. doi: 10.2337/dc12-1401. 
9) Fagher K, Katzman P, Löndahl M. Transcutaneous oxygen pressure as a predictor for short-
term survival in patients with type 2 diabetes and foot ulcers: a comparison with ankle 
brachial index and toe blood pressure. Acta Diabetol. 2018; 55(8):781-788. doi: 
10.1007/s00592-018-1145-8. 
10) Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, Drucker DJ. Cardiovascular Actions 
and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl 
Peptidase-4 Inhibitors. Circulation. 2017;136(9):849-870. doi: 
10.1161/CIRCULATIONAHA.117.028136. 
11) Xiao-Yun X, Zhao-Hui M, Ke C, Hong-Hui H, Yan-Hong X. Glucagon-like peptide-1 
improves proliferation and differentiation of endothelial progenitor cells via upregulating 
VEGF generation. Med Sci Monit. 2011;17:BR35-41. doi: 10.12659/msm.881383.  
12) Lund A, Knop FK, Vilsbøll T. Glucagon-like peptide-1 receptor agonists for the treatment 
of type 2 diabetes: Differences and similarities. Eur J Intern Med. 2014;25(5):407-14. doi: 
10.1016/j.ejim.2014.03.005. 
13) Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of 
exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for 
an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem. 
1992;267(11):7402-5. 
14) Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes 
in Type 2 Diabetes. N Engl J Med. 2016;375(4):311-22. doi: 10.1056/NEJMoa1603827. 
15) Marso SP, Bain SC, Consoli A, et al. Semaglutide and Cardiovascular Outcomes in Patients 
with Type 2 Diabetes. N Engl J Med. 2016;376(9):891-2. doi: 10.1056/NEJMc1615712.  
16) Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in 
patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-
blind, randomised placebo-controlled trial. Lancet. 2018; 392(10157):1519-1529. doi: 
10.1016/S0140-6736(18)32261-X.  
17) Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in 
type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 
2019;394(10193):121-130. doi: 10.1016/S0140-6736(19)31149-3.  
18) Dhatariya K, Bain SC, Buse JB, et al. The Impact of Liraglutide on Diabetes-Related Foot 
Ulceration and Associated Complications in Patients With Type 2 Diabetes at High Risk for 
Cardiovascular Events: Results From the LEADER Trial. Diabetes Care. 2018;41(10):2229-
2235. doi: 10.2337/dc18-1094. 
 
 


12 
 
 
 
 
 
 
 
 
 
 
The trial was approved by the local ethical committee on 13.01.2021. It was conducted between 
February 2021 and December 2022 at the Division of Endocrinology and Metabolic Diseases of 
University of Campania “Luigi Vanvitelli”, Naples, Italy, in accordance with the Declaration of 
Helsinki.